MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Subcutaneous apomorphine reduces OFF time and dyskinesias and improves quality of life in Parkinson’s disease (PD) – 5-year follow-up of patients in Greece

G.A. Tagaris, A. Skafida, D. Athanasopoulos, E. Trachani, S. Tsiara (Athens, Greece)

Meeting: 2016 International Congress

Abstract Number: 1881

Keywords: Apomorphine, Dyskinesias, Parkinsonism

Session Information

Date: Thursday, June 23, 2016

Session Title: Parkinson's disease: Clinical trials, pharmacology and treatment

Session Time: 12:00pm-1:30pm

Location: Exhibit Hall located in Hall B, Level 2

Objective: To evaluate the long-term efficacy of subcutaneous apomorphine (APO) injection and APO infusion in controlling motor fluctuations and dyskinesias and the impact on quality of life (QoL) of PD patients at a single centre in Greece. To examine the effects of switching from injection to infusion on outcomes.

Background: Subcutaneous APO is an effective treatment for motor symptoms in PD patients who experience fluctuations despite receiving optimised oral medication. It can be given as an intermittent injection to patients who have a few OFF episodes per day or as a continuous infusion to patients with more advanced disease who have frequent or long OFF periods, or those who want minimally invasive, reversible continuous dopaminergic stimulation. Data reporting clinical outcomes and effect on patients’ activities of daily living (ADL) with long-term use of APO in the ‘real world’ setting, including transitions from injection to infusion, are limited.

Methods: A retrospective evaluation of outcomes in 19 PD patients (12 male, 7 female) either treated initially with APO injection then switched to APO infusion (n=15) or those treated with infusion only (n=4). Data were obtained from medical records. To assess QoL, ADL score was determined at 6 months using a questionnaire.

Results: Patients had a disease duration of 2–22 years at treatment onset. Mean follow-up was 23.7 months for patients treated with APO injection and 31.7 months for those switched to, or started on, APO infusion. Mean daily OFF time was 7.37 hours (h) at baseline which reduced to 2.07 h with APO injection treatment and to 1.05 h with APO infusion. Mean total daily ON time without dyskinesia was 4.5 h at baseline, 9.20 h with APO injection treatment and 14.76 h for APO infusion. 6 months after starting APO infusion, 42% (8/19) patients had reduced their daily levodopa dose. Compared with baseline (15.16) patients’ mean ADL scores improved with APO injection treatment (13.67) and still further with APO infusion (11.58).

Conclusions: These data confirm that both APO injection and infusion show sustained clinical efficacy in PD patients with long-term use and that APO infusion is levodopa sparing. APO treatment also improves patients’ ability to undertake usual activities thus helping to maintain independence.

To cite this abstract in AMA style:

G.A. Tagaris, A. Skafida, D. Athanasopoulos, E. Trachani, S. Tsiara. Subcutaneous apomorphine reduces OFF time and dyskinesias and improves quality of life in Parkinson’s disease (PD) – 5-year follow-up of patients in Greece [abstract]. Mov Disord. 2016; 31 (suppl 2). https://www.mdsabstracts.org/abstract/subcutaneous-apomorphine-reduces-off-time-and-dyskinesias-and-improves-quality-of-life-in-parkinsons-disease-pd-5-year-follow-up-of-patients-in-greece/. Accessed May 21, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/subcutaneous-apomorphine-reduces-off-time-and-dyskinesias-and-improves-quality-of-life-in-parkinsons-disease-pd-5-year-follow-up-of-patients-in-greece/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • The hardest symptoms that bother patients with Parkinson's disease
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Patients with Essential Tremor Live Longer than their Relatives
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Welcome to the MDS Abstracts Site
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • The hardest symptoms that bother patients with Parkinson's disease
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley